These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8402715)

  • 1. Use of anti-CD3 and anti-CD16 bispecific monoclonal antibodies for the targeting of T and NK cells against tumor cells.
    Ferrini S; Cambiaggi A; Sforzini S; Canevari S; Mezzanzanica D; Colnaghi MI; Moretta L
    Cancer Detect Prev; 1993; 17(2):295-300. PubMed ID: 8402715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering molecules.
    Ferrini S; Cambiaggi A; Cantoni C; Canevari S; Mezzanzanica D; Colnaghi MI; Moretta L
    Int J Cancer Suppl; 1992; 7():15-8. PubMed ID: 1428398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific monoclonal antibodies directed to CD16 and to a tumor-associated antigen induce target-cell lysis by resting NK cells and by a subset of NK clones.
    Ferrini S; Prigione I; Miotti S; Ciccone E; Cantoni C; Chen Q; Colnaghi MI; Moretta L
    Int J Cancer; 1991 May; 48(2):227-33. PubMed ID: 1826900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of T lymphocytes against EGF-receptor+ tumor cells by bispecific monoclonal antibodies: requirement of CD3 molecule cross-linking for T-cell activation.
    Ferrini S; Cambiaggi A; Sforzini S; Marciano S; Canevari S; Mezzanzanica D; Colnaghi MI; Grossi CE; Moretta L
    Int J Cancer; 1993 Dec; 55(6):931-7. PubMed ID: 8253530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of cytolytic activity in CD3- and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR.
    van de Griend RJ; Bolhuis RL; Stoter G; Roozemond RC
    J Immunol; 1987 May; 138(10):3137-44. PubMed ID: 2952709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
    Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
    Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16.
    Garcia de Palazzo I; Holmes M; Gercel-Taylor C; Weiner LM
    Cancer Res; 1992 Oct; 52(20):5713-9. PubMed ID: 1394194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promotion of natural killer cell growth in vitro by bispecific (anti-CD3 x anti-CD16) antibodies.
    Malygin AM; Somersalo K; Timonen T
    Immunology; 1994 Jan; 81(1):92-5. PubMed ID: 7510664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
    Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
    Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy with bispecific antibodies.
    Thielemans KM
    Verh K Acad Geneeskd Belg; 1995; 57(3):229-47; discussion 247-8. PubMed ID: 7483816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma.
    Lai P; Rabinowich H; Crowley-Nowick PA; Bell MC; Mantovani G; Whiteside TL
    Clin Cancer Res; 1996 Jan; 2(1):161-73. PubMed ID: 9816103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
    Demanet C; Brissinck J; Leo O; Moser M; Thielemans K
    Cancer Res; 1994 Jun; 54(11):2973-8. PubMed ID: 8187084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid induction of cytolytic T cells via CD28 stimulation for cellular immunotherapy.
    Blum S; Milesi R; Tratkiewicz J; Olive D; Gallati H; Cerottini JC; von Fliedner V
    Ther Immunol; 1994 Jun; 1(3):143-52. PubMed ID: 7584490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
    Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
    J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer.
    Boerman OC; Tibben JG; Massuger LF; Claessens RA; Corstens FH
    Anticancer Res; 1995; 15(5B):2169-74. PubMed ID: 8572619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3.
    Blank-Voorthuis CJ; Braakman E; Ronteltap CP; Tilly BC; Sturm E; Warnaar SO; Bolhuis RL
    J Immunol; 1993 Sep; 151(6):2904-14. PubMed ID: 8376761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-alpha.
    Yoshida J; Takaoka T; Mizuno M; Momota H; Okada H
    J Surg Oncol; 1996 Jul; 62(3):177-82. PubMed ID: 8667624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth.
    Qian JH; Titus JA; Andrew SM; Mezzanzanica D; Garrido MA; Wunderlich JR; Segal DM
    J Immunol; 1991 May; 146(9):3250-6. PubMed ID: 1826709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.